No Surgeries Needed: Immunotherapy Offers Hope for Early-Stage Cancer Patients (5 minutes reading)
A recent study published in the New England Journal of Medicine has revealed a promising new treatment for early-stage cancers. The immunotherapy drug dostarlimab, owned by GlaxoSmithKline, has shown remarkable results in eliminating tumors in patients with mismatch repair-deficient (dMMR) cancers.
Dostarlimab is a PD-1 blocking agent that helps the immune system recognize and attack cancer cells. This drug was used in a phase 2 study involving patients with stage I, II, or III dMMR solid tumors, including rectal and nonrectal cancers. The study included 117 patients who were treated with dostarlimab for six months. The results were impressive: 84 patients had a complete response to the treatment, meaning their tumors were eliminated, and 82 patients avoided surgery altogether. Recurrence-free survival at two years was 92%.
This breakthrough means that many patients can avoid invasive surgeries and preserve their organs, significantly improving their quality of life. The study's success offers hope for extending this treatment to other early-stage cancers. This innovative approach could revolutionize cancer treatment, providing a less invasive and more effective option for patients.
No comments:
Post a Comment